Drug Description
Each tablet contains 250 mg of gefitinib. Excipient: Each tablet contains 163.5 mg of lactose (as monohydrate)
Presentation
Filmcoated tablet (tablet). Tablets are brown, round, biconvex, impressed with “IRESSA 250” on one side and plain on the other
Indications
IRESSA is indicated for the treatment of adult patients with locally advanced or metastatic nonsmall cell lung cancer (NSCLC) with activating mutations of EGFRTK.
Adult Dosage
Treatment with IRESSA should be initiated and supervised by a physician experienced in the use of anticancer therapies.
Posology
